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Introduction: Chronic hepatitis B (HBV) and C (HCV) virus infection is associated
with the activation of hepatic stellate cells (HSCs) toward a myofibroblastic phenotype,
resulting in excessive deposition of extracellular matrix, the development of liver fibrosis,
and its progression toward cirrhosis. The gold standard for the detection and staging
of liver fibrosis remains the liver biopsy, which is, however, associated with some mild
and severe drawbacks. Other non-invasive techniques evade these drawbacks, but lack
inter-stage specificity and are unable to detect early stages of fibrosis. We investigated
whether circulating vesicle-associated miRNAs can be used in the diagnosis and staging
of liver fibrosis in HBV and HCV patients.
Methods: Plasma samples were obtained from 14 healthy individuals and 39 early stage
fibrotic patients (F0–F2) with chronic HBV or HCV infection who underwent transient
elastography (Fibroscan). Extracellular vesicles were extracted from the plasma and the
level of miRNA-122, -150, -192, -21, -200b, and -92a was analyzed by qRT-PCR in
total plasma and circulating vesicles. Finally, these same miRNAs were also quantified
in vesicles extracted from in vitro activating primary HSCs.
Results: In total plasma samples, only miRNA-200b (HBV: p = 0.0384; HCV:
p = 0.0069) and miRNA-122 (HBV: p < 0.0001; HCV: p = 0.0007) were significantly
up-regulated during early fibrosis. In circulating vesicles, miRNA-192 (HBV: p < 0.0001;
HCV: p < 0.0001), -200b (HBV: p < 0.0001; HCV: p < 0.0001), -92a (HBV: p < 0.0001;
HCV: p < 0.0001), and -150 (HBV: p = 0.0016; HCV: p = 0.004) displayed a significant
down-regulation in both HBV and HCV patients. MiRNA expression profiles in vesicles
isolated from in vitro activating primary mouse HSCs resembled the miRNA expression
profile in circulating vesicles.
Conclusion: Our analysis revealed a distinct miRNA expression pattern in total plasma
and its circulating vesicles. The expression profile of miRNAs in circulating vesicles
of fibrotic patients suggests the potential use of these vesicle-associated miRNAs as
markers for early stages of liver fibrosis.
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INTRODUCTION
Liver fibrosis is the pathological condition of the liver resulting
from sustained wound healing in response to various causes of
chronic liver injury, including chronic hepatitis B virus (HBV)
and hepatitis C virus (HCV) infection (Friedman, 2003; Wallace
et al., 2008). The main collagen producing cell type in this
pathological process is the hepatic stellate cell (HSC), which is a
liver-resident cell, located in the Space of Disse, that can activate
toward a myofibroblastic (fibrotic) state during chronic liver
injury (Hautekeete and Geerts, 1997). This activation process is
associated with major changes in the gene-expression profile of
the stellate cell (Mann and Smart, 2002; De Minicis et al., 2007),
with as most important consequence, a dysregulation of the
production of extracellular-matrix proteins, and thus excessive
deposition and accumulation of extracellular matrix (ECM) in
the parenchyma of the liver (Li and Friedman, 1999). Liver
fibrosis can progress to a cirrhosis, characterized by a loss of liver
function, and even hepatocellular carcinoma (HCC) (Schuppan
and Afdhal, 2008). Liver disease remains a global burden, as
demonstrated by a study of the Global Burden of Disease (GBD)
project, which estimated in 2010 a death toll of over one million
deaths due to liver cirrhosis, and an additional one million deaths
due to liver cancer and acute hepatitis (Lozano et al., 2012; Byass,
2014).
The diagnosis of liver fibrosis can be made by routine
examinations, but the gold standard remains the liver biopsy,
which identifies the underlying cause, assesses the necro-
inflammatory grade and identifies the stage of fibrosis (Friedman,
2003). This diagnostic procedure is however, invasive and is
associated with a small risk of pain, and very rarely bleeding or
other severe complications (Thampanitchawong and Piratvisuth,
1999; Bravo et al., 2001). In addition, due to inter-observer
variability and sample errors, there is a possibility of under- or
over-rating the specific stage of liver fibrosis (Maharaj et al.,
1986; Regev et al., 2002). Because of these drawbacks, researchers
use several non-invasive techniques to measure the degree of
liver fibrosis, including scoring systems evaluating biochemical
parameters such as the Fibrotest score (Imbert-Bismut et al.,
2001) and the aspartate transaminase to platelet ratio index
(APRI) test (Wai et al., 2003), and imaging techniques such as
transient elastography (Fibroscan) (Sandrin et al., 2003; Foucher
et al., 2006). Although many of the non-invasive techniques
have a significant predictive value for the diagnosis of later
stages of liver fibrosis, being significant liver fibrosis and liver
cirrhosis, many of these systems have not been validated for
the identification of early stages of disease progression or to
discriminate between the various stages (Adams, 2011; Sharma
et al., 2014).
One potential new diagnostic method for the identification
and follow up of liver fibrosis progression could be the analysis of
circulating miRNAs. MiRNAs are short RNA sequences of ∼22
nucleotides that regulate gene expression post-transcriptionally
and can be found both in the intra- and extracellular environment
(Bartel and Chen, 2004; Lee, 2013). MiRNAs obtain extracellular
stability thanks to binding with lipids, proteins, and packaging
into extracellular vesicles (ECVs) (Turchinovich et al., 2012).
This latter group consists of small membrane-derived vesicles,
of which 2 subtypes can be found in the blood stream: larger
(100 nm-1 µm in diameter) vesicles, also known as microvesicles
or shedding vesicles (Camussi et al., 2010), and smaller vesicles
(30–100 nm in diameter), also known as exosomes (Thery
et al., 2002). Interestingly, an increased number of circulating
vesicles has been shown in mice and humans with alcoholic
hepatitis (Momen-Heravi et al., 2015) and in murine models
of NAFLD (Povero et al., 2014). In addition, communication
experiments have proven the functionality of miRNA-baring
vesicles in various aspects of the liver fibrosis process, such as
HSC activation status (Charrier et al., 2014; Wang R. et al., 2015),
and angiogenesis (Witek et al., 2009; Povero et al., 2013). Their
increased presence during liver fibrosis and their importance in
cell communication makes circulating ECVs potential candidates
to act as biomarkers for liver fibrosis.
Based on the major ECM-producing character of activating
HSCs during the process of liver fibrosis (Hautekeete and
Geerts, 1997; Atzori et al., 2009), we hypothesized that HSCs
contribute to this increase in circulating ECVs. In this study,
we compared total circulating miRNAs with ECV-associated
miRNAs for their ability to be used as a diagnostic tool for
early stage liver fibrosis caused by chronic HBV and HCV
infection. After identification of miRNAs that are differentially
regulated during the process of HSC activation, we analyzed
which group of circulating miRNAs could better represent this
changing HSC status. Our data shows that the selected miRNAs
do not display the same expression patterns in ECVs and total
plasma during early stage liver fibrosis by chronic HBV and HCV
infection, and that ECV-associated miRNAs display a tendency of
representing the changing cellular miRNA content during HSC
activation.
MATERIALS AND METHODS
Isolation and Culture of Mouse HSCs
The university’s guidelines for the care and use of laboratory
animals in research were strictly followed and the study was
approved by the ethical committee of the Vrije Universiteit
Brussel in project 15-212-1. Quiescent HSCs were isolated
from male Balb/c mice (Charles River Laboratories, L’Arbresle,
France) (25–30 weeks old) as described earlier (Mannaerts
et al., 2010). After isolation, mouse HSCs were cultured in
Dulbecco’s modified Eagle’s medium (Lonza, Verviers, Belgium)
supplemented with 10% Exosome-depleted fetal bovine serum
(System Biosciences, Mountain View, USA), 2 Mm L-glutamine
(Ultraglutamine 1 R©) (Lonza), 100 U/ml penicillin and 100 µg/ml
streptomycin (Pen-Strep R©) (Lonza).
Patient Population
Between October 2015 and July 2016 39 patients were recruited.
Patients presented at the department of Gastro-enterology and
Hepatology of the UZ Brussel with chronic liver disease caused
by Hepatits B or C infection underwent a Fibroscan R© (Echosens,
Paris, France). None of the patients was under treatment for
HBV or HCV infection. Patients who were pregnant, or had a
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concomitant disease that could possibly bias the results (such
as HIV, alcohol abuse) were excluded. A healthy population of
14 individuals was recruited as a control group. In this healthy
population, liver function was not tested, but none of the subjects
had a history of liver disease, and all subjects were declared
healthy after the annual exam by the occupational physician.
Characteristics of the study cohort are listed in Table 1. The study
was performed according to the principles of the declaration
of Helsinki, and approved by the ethical committee of the
UZ Brussel and Vrije Universiteit Brussel (reference number
2015/297). Written informed consent was obtained from every
participant before enrolment.
Assessment of Liver Fibrosis
Staging of liver fibrosis was assessed by Fibroscan (Echosens,
Paris, France), a device based on transient elastography. Only
patients with at least 10 valid liver stiffness measurements, with
an interquartile range of less than 30% of the median liver
stiffness, and with a success rate of at least 60% were included
in the study. Patients who presented with a liver stiffness below
9.5 kPa were considered having no significant or moderate
liver fibrosis (F0-F1-F2). This cut-off value is based on current
literature, and can be used for both patients infected with HBV as
with HCV (Wang et al., 2009). No patients with liver stiffness of
9.5 kPa or more (corresponding to advanced liver fibrosis or liver
cirrhosis) were included in the study population.
Plasma Collection and Storage
Blood samples were collected by venepuncture into Sarstedt
S-monovette EDTA 9ml tubes (Sarstedt AG & Co, Nümbrecht,
Germany) at the department of Gastro-enterology and
Hepatology of the UZ Brussel. Samples were kept on ice
and were processed within 1 h of collection by a two-step
centrifugation process consisting of 1500 g for 10 min followed
by 2000 g for 3 min to eliminate any remnant cells. The
supernatant was transferred to RNase/DNase-free tubes and
stored at−80◦C until further use.
Plasma miRNA Analysis
Five hundred microliter of plasma was used. Plasma miRNA was
extracted using the Nucleospin R© miRNA Plasma kit (Macherey-
Nagel, Düren, Germany) using the manufacturers protocol.
Caenorhabditis elegans miRNA-39 (cel-miR-39) (Qiagen, Hilden,
Germany) was spiked into the plasma lysate before extraction,
and served as an external processing control.
Vesicle Isolation and Analysis from
Plasma and Cell Culture Medium
Five hundred microliter of plasma was mixed with Total Exosome
Isolation (TEI) reagent (Thermo Fisher scientific, Waltham,
MA, USA), and isolation was performed according to the
manufacturer’s protocol. In summary, the plasma sample was
depleted of debris by a two-step centrifugation of 20 min at
2000 and 10000 g. After incubating the plasma sample for
10 min at room temperature with the reagent, vesicles were
precipitated by centrifugation at 10000 g, and resuspended in
a volume of PBS. For the isolation of vesicles from culture
medium (CM), 4 ml of CM was centrifuged for 30 min at 2000 g,
to remove any contaminating debris, followed by overnight
incubation with the TEI precipitation reagent, and centrifugation
for 1 h at 10000 g to generate a vesicle-rich pellet. The obtained
vesicle suspensions from plasma and CM were purged from
contaminating proteins by incubation with 0.5 mg proteinase K
(Thermo Fisher scientific) for 30 min at 55◦C. Total RNA was
TABLE 1 | Baseline characteristics of included patients.
HBV-infected HCV-infected Healthy
Individuals (n) 19 20 14
Male/Female (n) 11/8 8/12 6/8
Age (years) 43.00 ± 13.76 54.30 ± 16.85 36.62 ± 15.10
BMI (kg/m2) 26.56 (24.08–29.03) 25.83 (22.52–27.48)
Scoring systems
Liver stiffness (kPa) 4.500 (3.800–6.100) 5.900 (3.900–7.100)
FIB-4 index 1.230 (0.6750–2.308) 1.900 (1.050–2.840)
Blood parameters
ALT (IU/L) 40.00 (25.50–59.25) 40.50 (25.75–67.75)
AST (IU/L) 31.50 (24.00–49.25) 41.50 (27.00–65.00)
Alkaline phosphatase (IU/L) 64.00 (47.25–71.50) 66.00 (51.50–85.00)
GGT (IU/L) 22.00 (17.25-37.75) 43.00 (19.50-135.50)
Total bilirubine (mg/dL) 0.5450 (0.4375–0.8850) 0.6050 (0.3800–0.8425)
Albumin (g/L) 44.50 (42.25–45.75) 43.00 (41.00–46.00)
INR 1.100 (1.000–1.100) 1.000 (1.000–1.150)
Alfa-fetoprotein (kIU/L) 2.900 (2.300–3.800) 3.850 (2.800–5.800)
Platelet count (103/mm3) 179.5 (148.8–220.5) 249 (205.0–321.0)
Serum creatinine (mg/dL) 0.9050 (0.7925–0.9450) 0.9400 (0.6700–1.040)
Ages are given as means ± SD, other parameters are givens as medians (IQR). BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; FIB-4, fibrosis-4;
AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase; INR, international normalized ratio.
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extracted from these vesicles by use of the Quick RNA miniprep
(Zymo Research, Irvine, CA, USA). Synthetic spike-in cel-miR-
39 was added to the vesicle lysate before proceeding with the
manufacturer’s protocol.
Quantitative Real-Time Polymerase
Chain Reaction
Both total RNA obtained from the vesicle fraction, and miRNAs
obtained from the plasma were reverse transcribed to cDNA
by use of miScript II RT kit (Qiagen, Hilden, Germany).
Total cell RNA was extracted and purified using the Reliaprep
RNA cell Miniprep System (Promega, Madison, WI, USA) and
converted to cDNA by reverse transcription using the Revert
Aid Kit (ThermoFisher Scientific, St. Leon-Rot, Germany). The
expression profiles of selected mRNA/miRNA were analyzed
by the ABI 7500 Real time PCR system (Applied Biosystems,
Waltham, MA, USA) using the SYBR green PCR method. MiRNA
detection was established by use of the miScript Universal primer
in combination with miRNA-specific primers, listed in Table 2.
Primers used for detection of mRNA are listed in Table 3. The
quantitative value for a given miRNA and mRNA was obtained
by subtracting the cycle threshold of the internal reference
respectively cel-miR-39 and Gapdh, with the cycle threshold of
the analyzed miRNA or mRNA.
Protein Analysis and Western Blot
The vesicle pellet obtained by use of the Total exosome
isolation (TEI) reagent was lysed in 50 µl of RIPA buffer
supplemented with complete protease-inhibitors (Roche
Diagnostics, Mannheim, Germany) and PhosSTOP phosphatase-
inhibitors (Roche Diagnostics). Lysates were sonicated twice
(15 s) in a 4◦C water bath. Protein concentrations were
quantified using the Micro BCATM Protein assay kit (Thermo
Fisher Scientific) according to manufacturer’s instructions.
Twenty five microgram of vesicles extracted from plasma or
CM were for western blotting. Protein expression was assessed
using antibodies against CD63, TSG101 (both 1:200, Santa
Cruz Biotechnology, Dallas, TX, USA), β-actin, vimentin
(1:5000 and 1:500 respectively, Sigma–Aldrich, St.Louis, MO,
USA), collagen type I (1:1000, Abcam, Cambridge, UK), and
PDGFRβ (1:1000, GeneTex, Irvine, CA, USA). Calreticulin
TABLE 2 | miRNA-specific primers.
miRNA Mature miRNA primer
miR-92a-3p TATTGCACTTGTCCCGGCCTGT
miR-122-5p TGGAGTGTGACAATGGTGTTTG
miR-150-5p TCTCCCAACCCTTGTACCAGTG
miR-192-5p CTGACCTATGAATTGACAGCC
miR-200b-3p TAATACTGCCTGGTAATGATGA
miR-21-5p TAGCTTATCAGACTGATGTTGA
cel-miR-39-3p AGCTGATTTCGTCTTGGTAATA
All primers were ordered from Integrated DNA Technologies (IDT, Leuven, Belgium),
and are specific for detection of both human and murine miRNA-expression.
Lyophilized primers were dissolved in RNase-free water to obtain primer solutions
with a final concentration of 10 pmol/µl.
TABLE 3 | Messenger RNA (mRNA) primers.
Gene Messenger RNA (mRNA) primer
Gapdh FP: TCGAGATCGCCACCTACAG
RP: GTCTGTACAGGAATGGTGATGC
Lox FP: CTCCTGGGAGTGGCACAG
RP: CTTGCTTTGTGGCCTTCAG
Col1a1 FP: ACCTAAGGGTACCGCTGGA
RP: ACCTAAGGGTACCGCTGGA
Acta2 FP: CCAGCACCATGAAGATCAAG
RP: TGGAAGGTAGACAGCGAAGC
All primers were ordered from Integrated DNA Technologies (IDT, Leuven, Belgium),
and are specific for detection of murine mRNA-expression. Lyophilized primers
were dissolved in RNase-free water to obtain primer solutions with a final
concentration of 10 pmol/µl. FP, forward primer; RP, reverse primer.
(1:1000, Cell Signaling Technology, Danvers, MA, USA) was
used to verify absence of cell contamination. As positive
control, a protein cell lysate of the HepG2 cell line was
used.
Statistical Analysis
The statistical analysis was performed using the GraphPad
Prism 6 (GraphPad, Palo Alto, USA) statistical software. Results
are given as means ± standard deviation (SD). Analysis of
variance (ANOVA), followed by Tukey’s post-test was employed
for statistical analysis. The sufficiency of the sample size was
confirmed by a web-based calculator1, using in house preliminary
results and a type I error rate (α) of 5% and a power (1-β)
of 80%. Receiver operating characteristic (ROC) curves were
constructed, and the area under the curve (AUC) was calculated
as accuracy index for the diagnostic performance of the selected
miRNAs. Results were considered statistically significant when
P< 0.05.
RESULTS
Clinical Characteristics of the Patient
Population
A cohort of 39 patients with early liver fibrosis was enrolled into
this study, including 19 patients with chronic HBV infection, and
20 patients with chronic HCV infection. All patients underwent
transient elastography (Fibroscan) to exclude advanced stage
liver fibrosis or cirrhosis. Fourteen healthy individuals with
absence of liver disease symptoms or history of liver disease
were included as control population. Participant characteristics
and biochemical parameters are depicted in Table 1. The
two patient populations displayed no significant difference in
Fibroscan-determined liver stiffness. The platelet count was
slightly higher in the HCV infected population (p = 0.0317),
but no other parameters showed any significant difference. The
values of all biochemical parameters were in the normal reference
range, further indicating the absence of any severe fibrosis or
cirrhosis.
1http://powerandsamplesize.com/Calculators/
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Identification of Deregulated miRNAs in
Activated Human HSCs and in the
Circulation of Fibrotic Patients
To identify circulating miRNAs that might represent early
changes in the fibrotic liver, we turned to HSC activation, a key
process in this pathology. Upon chronic liver damage by HBV
or HCV infection, HSCs undergo an activation process toward
a myofibroblastic phenotype, which is associated with dynamic
changes in gene and miRNA expression profiles (De Minicis et al.,
2007; Coll et al., 2015). We hypothesized that those deregulated
miRNAs are secreted into the blood stream and their blood
levels might serve as markers for fibrosis progression. We probed
the literature for deregulated miRNAs previously identified in
activated human HSCs (Coll et al., 2015), for their prevalence
in the blood stream during liver disease (Table 4). MiRNA-
150, -192, and -200b were selected from this list as potentially
important miRNAs, based on their significant deregulation
during HSC activation and their changing expression in the blood
of patients with liver disease. MiRNA-122 was used as positive
control, as its changing expression in circulation has already been
widely described for various causes of liver fibrosis, including
HBV (Xu et al., 2011; Waidmann et al., 2012; Winther et al.,
2013) and HCV (Cermelli et al., 2011; Wang J.H. et al., 2015;
Motawi et al., 2016) and is strongly correlated with hepatocyte
damage (Farid et al., 2012; Roderburg et al., 2015). MiRNA-
92a and miRNA-21 were selected for their known presence in
circulating vesicles from patients with various pathologies (Skog
et al., 2008; Taylor and Gercel-Taylor, 2008; Rabinowits et al.,
2009; Chen et al., 2016), and their potential implication in liver
disease.
MiRNA-122, -192, and -200b Are
Up-Regulated in Total Plasma of Early
Stage Fibrotic Patients
The expression of selected miRNAs was first analyzed in total
plasma samples from early stage chronic HBV- and HCV-infected
fibrotic patients, and compared with the healthy control group
(Figure 1). Significantly higher expression of miRNA-122 in the
patient groups confirms earlier reports by Trebicka et al. (2013)
and Arataki et al. (2013), which showed that higher miRNA-
122 levels reflect early stages of chronic HCV and HBV induced
liver fibrosis. From our selected miRNAs, miRNA-21, -92a, and
-150 displayed no significant change in expression. MiRNA-192
was significantly up-regulated in HBV-patients, but not in HCV
patients, when compared with the control group. MiRNA-200b,
was significantly up-regulated in both HBV and HCV fibrotic
patients.
Early Stage Fibrotic Patients Have an
Increased Circulating ECV-Content With
Low Levels of miRNA-192, -92a, -200b,
and -150
Next, we analyzed the expression of the selected miRNAs in
vesicles isolated from plasma from healthy controls and patients
with HBV or HCV infection, using standardized precipitation
protocols (Schageman et al., 2013; Li et al., 2015) (Figure 2A).
Western blot analysis for the vesicle-enriched proteins CD63 and
TSG101 (Yoshioka et al., 2013; Kowal et al., 2016) demonstrates
the presence of vesicles in the preparations, while the cellular
protein calreticulin (Jeppesen et al., 2014) was absent (Figure 2B).
The expression of CD63, a tetraspanin family member, can be
seen as multiple bands for HCV and HBV patients, while healthy
subjects have a single band. This suggests a potential disease-
related presence of CD63 isoforms on the vesicle membrane.
All vesicle samples were negative for calreticulin, indicating the
absence of ‘contaminating’ cells in the vesicle suspension. As
an increase of circulating vesicles has been proven during the
process of alcoholic hepatitis (Momen-Heravi et al., 2015) and
murine models of non-alcoholic fatty liver disease (NAFLD)
(Povero et al., 2014), we also determined their relative presence
in early fibrotic HBV and HCV patients, compared to the healthy
control subjects. A significant enrichment of circulating vesicle-
content was found in HCV fibrotic patients, while a trend of
such enrichment was found in the HBV group (Figure 2C). As
both patient-groups have an equal distribution in liver stiffness, as
assessed by Fibroscan, and biochemical characteristics (Table 1),
we suggest that the level of enrichment of circulating ECVs is
disease-dependent.
Analysis of the vesicle samples for their miRNA cargo
showed that the expression profile of the selected miRNAs was
different from their profile in total plasma samples (Figure 3A).
While miRNA-122 levels were significantly up-regulated in total
plasma of both HBV and HCV fibrotic patients, we observed
a significant down-regulation of miRNA-122 in vesicles of the
HCV population, and no change in HBV samples. MiRNA-
21 shows, just as in the total plasma samples, no change
in expression in the vesicle preparations. A significant down-
regulation in vesicle-associated miRNA expression in both
patient groups could be seen for miRNA-192, -150, -92a,
and -200b. Analysis of these four latter miRNAs with use of
ROC plots identifies for all miRNAs a strong discriminative
potential between the healthy and fibrotic HBV and HCV
patient groups (Figure 3B). Especially miRNA-192 (HBV AUC:
0.9802; HCV AUC: 0.9762) and miRNA-200b (HBV AUC:
0.9699; HCV AUC: 0.9841) have an inherent potential to
be used as biomarker for the identification of early fibrosis
by chronic HBV and HCV infection. MiRNA-92a shows a
significant discriminative potential for HBV fibrotic patients
(AUC: 0.9595), while this is less for HCV fibrotic subjects (AUC:
0.8745).
Expression Patterns of miRNA-192, -92a,
and -200b Show an Overlap in
Circulating Vesicles and Activating HSCs
To determine whether the expression profile of miRNAs analyzed
in the ECV fractions could reflect the expression profile of
these miRNAs in activating HSCs, we investigated whether
these miRNAs are present in vesicles released from activating
HSCs. Hereto we collected vesicles from primary culture-
activated mouse HSCs and investigated their miRNA content.
First, HSC activation over a 10 days period was confirmed
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TABLE 4 | In silico analysis of miRNAs differentially regulated during activation of human HSCs (Coll et al., 2015) and in the circulation of patients with
liver disease.
Change of expression in human aHSC
(Fold Change)
Expression in plasma of liver disease-compared
to healthy individuals
Source
Expression trend Etiology
miRNA-150-5p ↓ (870) ↑ HBV Li et al., 2010; Venugopal et al.,
2010
miRNA-192-5p ↓ (8.53) ↑ HBV, NASH, NAFLD Tryndyak et al., 2012; Winther
et al., 2013; Becker et al., 2015;
Pirola et al., 2015
miRNA-200b-3p ↑ (22.55) ↑ NAFLD, HBV/HCV-associated HCC Murakami et al., 2011; Tryndyak
et al., 2012
miRNA-122-5p N.D. ↑ HCV, HBV, NASH, NAFLD Arataki et al., 2013; Shrivastava
et al., 2013; Tan et al., 2014;
Pirola et al., 2015
miRNA-21-5p N.D. = /↑ HBV, NAFLD Yamada et al., 2006; Cermelli
et al., 2011; Becker et al., 2015
miRNA-92a-3p N.D. ↑ HBV-associated HCC, HCV Li et al., 2010; Ji et al., 2011;
Shrivastava et al., 2013
N.D., non-determined.
FIGURE 1 | Plasma miRNAs are differentially regulated during early fibrosis in patients with chronic HBV and HCV infection. The plasma levels of
miRNA-122, -150, -192, -21, -200b, and -92a were measured by real-time quantitative PCR, and obtained Ct levels were normalized by use of spiked-in
cel-miRNA-39. The miRNA expression levels in plasma of F0/F1/F2 patients with chronic HBV and HCV infection were compared with healthy control subjects.
∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001.
by the change in morphology of the HSCs (Figure 4A) and
the increasing expression of the activation markers Acta2,
Col1a1, and Lox (Figure 4B). During this activation process,
the cellular expression of the 3 miRNAs that were identified
as potential vesicle-associated fibrosis markers (miRNA -192, -
200b, and -92a) and a control miRNA (miRNA-21) were analyzed
(Figure 4D). MiRNA-21 shows a relatively stable expression,
while levels of miRNA-192, -92a, and -200b are all down-
regulated in activated HSCs. Vesicles extracted from the culture
medium were characterized by western blot for the presence
of CD63 and the absence of calreticulin (Figure 4C). The
miRNA content of these vesicles displayed overlap with their
cellular expression, as miRNA-21 was stable, miRNA-192 was
significantly down-regulated, and miRNA-92a, and -200b show
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FIGURE 2 | Isolation of extracellular vesicles from plasma. (A) ECVs were extracted from 0.5 ml plasma obtained from F0/F1/F2 patients with chronic HBV
and HCV infection, and a healthy control group. After centrifugation, a vesicle-rich pellet is obtained, which is dissolved in PBS for further analysis. (B) Obtained
vesicle-suspensions were analyzed by western blot for expression of the vesicle-markers CD63 and TSG101, and the absence of the cellular marker calreticulin.
(C) Protein content of ECVs isolated from different groups. An increase in protein concentration can be seen comparing vesicle-preparations of healthy subjects with
HBV and HCV patients. ∗∗P < 0.01.
clear trends of being down-regulated during HSC activation
(Figure 4E).
DISCUSSION
Liver fibrosis and cirrhosis are slowly progressing consequences
of chronic liver damage and the incredible regenerative capacity
of the liver impedes the early detection of fibrosis. Over the
years, many have tried to develop sensitive, non-invasive methods
for detection of liver fibrosis and cirrhosis. While the potential
of circulating miRNAs is becoming clearer, most studies used
cohorts of severe fibrotic and cirrhotic patients (Cermelli et al.,
2011; Bala et al., 2012; Chen et al., 2013; Roderburg and Luedde,
2014). In this manuscript we investigated HSC-related miRNAs
in ECVs isolated from early stage HBV and HCV plasma samples.
We show that ECV-associated miRNA levels change in these
patients when compared with healthy control plasma and we
suggest that ECV-associated miRNAs can represent the activation
status of the scar producing HSC.
Circulating vesicles have been explored extensively as
diagnostic tools for cancer (Duijvesz et al., 2011; Cazzoli
et al., 2013; Ogata-Kawata et al., 2014; Thakur et al., 2014).
For example, Sohn et al. (2015) analyzed the expression
of ECV-associated miRNAs between a cirrhotic population,
patients with hepatocellular carcinoma (HCC), and a chronic
HBV-infected control group. They suggest that total plasma
miRNAs in comparison with ECV-associated miRNAs were
less suitable to discriminate between HCC and HBV (Sohn
et al., 2015). In accordance with these observations we describe
significantly lower levels of miRNAs-192, -92, and -200b in
hepatitis ECVs, while they have no diagnostic value when
analyzed in total plasma.
Because HSCs are the main cellular source of scar proteins, we
hypothesized that HSCs could also be a source of ECV-associated
miRNAs in the circulation of fibrotic patients. MiRNA-192 was
significantly up-regulated in total plasma of early stage HBV
patients (Figure 1), but it shows significant down-regulation in
the ECVs extracted from both HBV- and HCV-infected patient
populations when compared to healthy subjects (Figure 3A).
Additionally, analysis of cell lysates and ECVs extracted from
the CM of in vitro activating HSCs show the same significant
decreasing levels of miRNA-192 (Figures 4D,E). In previous
work, we showed that also in vivo activated mouse HSCs and total
liver samples of cirrhotic patients with superimposed alcoholic
hepatitis show such significant down-regulation of cellular
miRNA-192. Over-expression of miRNA-192 leads to less cell
proliferation and less PDGF-induced migration (Coll et al., 2015),
suggesting that miRNA-192 might play a role in suppressing HSC
activation. Analysis of potential targets of the down-regulated
ECV-associated miRNAs by TargetScan (Supplementary Table 1),
identified various genes involved in some fundamental processes
of HSC activation, such as cell migration, cell proliferation,
ECM organization, and signaling by transforming growth factor
Frontiers in Pharmacology | www.frontiersin.org 7 February 2017 | Volume 8 | Article 56
fphar-08-00056 February 7, 2017 Time: 15:15 # 8
Lambrecht et al. ECV-Associated miRNAs as Biomarkers of Liver Fibrosis
FIGURE 3 | Expression of vesicle-associated miRNA-150, -192, -200b, -92a during early stage HBV- and HCV-induced fibrosis. (A) The levels of plasma
vesicle-associated miRNA-122, -150, -192, -21, -200b, and -92a were measured by real-time quantitative PCR, and obtained Ct levels were normalized by use of
spiked-in cel-miRNA-39. (B) Curves of receiver operating characteristic (ROC) analysis using the differentially expressed vesicle-associated miRNA-150, -192,
-200b, and -92a for discriminating early stage HBV (blue) and HCV (red) fibrotic patients versus healthy controls. ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001.
beta (TGFβ) (Reeves and Friedman, 2002; Friedman, 2003).
This underlines the importance of the selected miRNAs in
the activation process of the HSCs, and suggests a potential
transmission of cellular status when transmitted to nearby HSCs
by ECV communication, a mechanism that has already been
studied in vitro (Chen et al., 2014).
We acknowledge that based on our ECV preparation we
cannot really determine the contribution of HSCs to the
circulating vesicle population. We did probe the obtained ECVs
for presence of HSC-related markers (Supplementary Figure 1).
Analysis of our vesicle populations for collagen type I (Lee et al.,
1995) and platelet-derived growth factor receptor beta (PDGFRβ)
(Borkham-Kamphorst et al., 2004; Thoen et al., 2011), showed
an enhanced expression in the patient populations with early
liver fibrosis, as compared to the healthy controls. Expression of
vimentin, a fibroblast-associated intermediate filament known to
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FIGURE 4 | In vitro activating mouse HSCs; cellular and vesicle miRNA content. Culture of primary mouse HSCs on regular tissue culture plates leads to the
spontaneous initiation of the activation process toward a myofibroblastic phenotype, as can be seen by (A) a change in morphology of the cells and (B) the
upregulation of the activation-associated markers Acta2, Lox, and Col1A1. (C) Vesicles isolated at different time points of the culture were verified for the presence of
CD63 and beta-actin, and the absence of the negative marker calreticulin. Expression of miRNA-21, -92a, -192, and -200b was analyzed both in (D) cell lysates and
(E) shedded vesicles extracted from in vitro activating HSCs by real-time quantitative PCR. Expression is calculated relative to the quiescent (day 2) time point.
∗P < 0.05; ∗∗P < 0.01; ∗∗∗∗P < 0.0001.
have a constant expression during HSC activation (Van Rossen
et al., 2014), was equally expressed in ECV populations of
healthy and sick individuals. These selected markers are not
unique for liver, but within the liver they are highly expressed
in HSCs and suggest the possibility of HSC-derived ECVs to
contribute to the total circulating ECV population. Ideally,
HSC- specific ECVs should be isolated from the patient plasma
samples. For this purpose, future studies could rely on the
presence of PDGFRβ on ECVs for use in cell type-specific
vesicle isolation strategies (Hong et al., 2014; Wang et al., 2016).
Unfortunately, these methods are not widely used and still
require optimization.
Of our analyzed miRNAs, miRNA-122 has been the most
widely described and is considered a liver specific miRNA.
Its expression in liver reduces upon injury, while significantly
more miRNA-122 is detected in total plasma of fibrotic patients.
Circulating miRNA-122 appears to mirror the histological and
molecular events occurring in the liver and correlates with
the degree of damage as measured by serum ALT levels.
This correlation has been shown in advanced fibrotic NASH-
patients (Pirola et al., 2015), NAFLD patients (Tan et al.,
2014), and chronic HCV infected patients (Shrivastava et al.,
2013). In this latter patient group, significant higher levels of
circulating miRNA-122 could be seen in early stage (F0–F2)
fibrosis, as compared to advanced fibrosis (F3–F4) (Trebicka
et al., 2013). Also in our experiments, an enhanced presence
of miRNA-122 could be found in the total plasma of early
stage HBV- and HCV-infected patients. A potential explanation
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for this event could be the discharge of this miRNA by
hepatocytes, as this cell type has inherent abundant levels
of miRNA-122 (Pirola et al., 2015). During progression of
liver fibrosis to cirrhosis, significant reduction of miRNA-
122 can be seen in total liver tissue, which is reflected by
the reduced circulating miRNA-122 levels during later stages
of fibrosis (Trebicka et al., 2013) and potentially the result
of less pronounced hepatocyte damage at these stages of
disease. In our experiments, the levels of miRNA-122 were
not affected in circulating ECVs from early fibrosis stage
HBV and HCV patients. However, in the research of Bala
et al. (2012), elevated levels of vesicle-associated miRNA-122
were found when comparing murine models of alcohol- and
inflammation-induced liver disease with a control population.
These findings were later confirmed in in vitro-experiments,
where APAP-treated hepatocytes released ECVs that were rich
in miRNA-122 (Holman et al., 2016). The extent of hepatocyte
damage can of course differ between rather short term liver
injury in rodents, in vitro induced hepatocyte toxicity, and
chronic hepatitis infected patients. Together, our observations
and the studies of Bala et al. (2012) and Holman et al.
(2016) suggest that different settings of liver injury leading to
hepatocyte death could be associated to ECV release of specific
miRNAs.
Although our results suggest the possibility of these circulating
vesicles to be used as part of a novel biomarker panel, we
recognize that our study has limitations, such as the limited
number of subjects included. However, even with this limited
amount of subjects, significant changes could be found in the
miRNA levels of total plasma and circulating ECVs. Analysis
of larger cohorts of patients and of different etiologies will
increase power and can perhaps provide the necessary evidence
to include one or more of the proposed miRNAs in a future
medical diagnostic panel for early stage liver fibrosis. Moreover,
it could be interesting to include patient groups with late-stage
(F3–F4) fibrosis to analyze their miRNA-associated ECV content.
A second limitation is the absence of precise fibrosis staging
of our included patients by liver biopsy. However, the use of
transient elastography (Fibroscan) has already been extensively
tested and validated for staging fibrosis in patients with viral
hepatitis, and has been shown to be highly specific for excluding
advanced fibrosis (Sterling et al., 2006; Afdhal et al., 2015). We
have used this Fibroscan technique in combination with Fib-
4 scoring, which has a negative predictive value of 90% for
advanced liver fibrosis (Ishak stage 4–6), and which has been
shown to be able to discriminate between fibrosis stage F0–2
and F3–4 (Verlinden et al., 2015; Zhang et al., 2016). The
combination of these 2 predictive values, plus the confirmation
of elevated levels of miRNA-122 in the total plasma of our
patients, ensured us we had a patient population with exclusively
early fibrotic patients. A third limitation is the fact that we
only look at six miRNAs in the current study. With this study
we wanted to investigate whether miRNAs that are related to
HSC activation, could be detected in total plasma or circulating
ECVs from patients with early stage liver fibrosis. Unbiased RNA
sequencing of HSC-derived ECVs could identify other potential
disease-specific biomarkers. This study also does not implicate
that vesicle-associated miRNAs are a better biomarker than total
plasma miRNA, but suggests that the use of vesicle-associated
miRNAs indeed could give a more sensitive representation of the
status of specific cell types, in this case the activation status of
HSCs. Circulating ECVs could be a significant addition to current
non-invasive biomarker panels to become even more sensitive for
fibrosis progression, and for detection of early and small changes
in fibrosis resolution. The former serves to identify patients at risk
to develop advanced fibrosis, while the latter would be of great
value for studying anti-fibrotic effects of drugs: if small changes
could be more easily detected, the duration of clinical trials could
be shortened.
CONCLUSION
We found a significant difference in the miRNA expression
profiles of total plasma and circulating ECVs from early fibrotic
HBV/HCV-infected patients. Our results suggest the use of ECV-
associated miRNAs as markers for the presence or absence of
activated HSCs and thus early stage liver fibrosis.
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